Opportunity Information: Apply for RD AL RDAAL 26 001
Apply for RD AL RDAAL 26 001
- The Office of National Drug Control Policy in the health sector is offering a public funding opportunity titled "Applied Drug Policy Research Experiences" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 95.007.
- This funding opportunity was created on 2026-08-06.
- Applicants must submit their applications by 2026-09-06. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $100,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Public and State controlled institutions of higher education, Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Applied Drug Policy Research Experiences grant opportunity is a discretionary federal funding program offered by the Office of National Drug Control Policy (ONDCP) to create hands-on, applied research experiences focused on real-world drug policy needs. The central aim is to build a structured program in which graduate students and recent post-graduates carry out rigorous research studies and advanced data analyses that directly support the National Drug Control Strategy. In practice, the funded project is expected to function like an applied research pipeline: training early-career researchers while generating timely, policy-relevant findings that can be used by decision-makers across public health and public safety.
The research focus is on understanding rapid changes in the illicit drug landscape and how those changes connect to patterns of drug use and related harms. This includes studying dynamic shifts in illicit drug supply, shifts in use behaviors, and the consequences that follow, such as overdoses and other health and safety impacts. A core purpose is to strengthen early warning and situational awareness so that officials can spot emerging drug threats sooner, anticipate outbreaks, and respond faster with interventions that better protect the public. The opportunity emphasizes applied, actionable work rather than purely academic outputs, with an orientation toward practical insights that can inform strategy, preparedness, and response.
Funding is provided through a cooperative agreement, which typically indicates substantial federal involvement during the period of performance, such as collaboration on priorities, coordination, or technical guidance, rather than a hands-off grant model. ONDCP expects to make one award under this opportunity, with an award ceiling of $100,000. The opportunity was created on August 6, 2026, and the original application closing date is September 6, 2026, making it a short timeline for applicants to prepare proposals.
Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, and nonprofit organizations with 501(c)(3) status (excluding institutions of higher education under that specific nonprofit category). The program is listed under a health-related funding activity category and is associated with CFDA number 95.007. The funding opportunity number is RD-AL-RDAAL-26-001, which applicants would use to locate the full announcement and submission instructions in the official system.
Overall, this opportunity is designed to do two things at once: develop the next generation of applied drug policy researchers and produce high-quality analyses that help government and community partners respond more effectively to a quickly evolving illicit drug environment.
Applied Drug Policy Research Experiences (ONDCP) - Frequently Asked Questions
1) What is the Applied Drug Policy Research Experiences funding opportunity?
This is a discretionary federal funding opportunity offered by the Office of National Drug Control Policy (ONDCP) to create hands-on, applied research experiences that address real-world drug policy needs. The funded work is expected to generate timely, policy-relevant findings that support the National Drug Control Strategy.
2) What is the main purpose of this program?
The central aim is to build a structured program where graduate students and recent post-graduates conduct rigorous research studies and advanced data analyses connected directly to practical drug policy priorities. The project is intended to function like an applied research pipeline that both trains early-career researchers and produces actionable results for decision-makers in public health and public safety.
3) What kinds of research topics does ONDCP want to support?
The research focus is on rapid changes in the illicit drug landscape and how those changes relate to patterns of drug use and drug-related harms. This includes studying dynamic shifts in illicit drug supply, changes in use behaviors, and resulting consequences such as overdoses and other health and safety impacts.
4) What does "applied" research mean in this context?
The opportunity emphasizes applied, actionable work rather than purely academic outputs. The expectation is that findings will be practical and usable for strategy, preparedness, and response, helping officials and partners make decisions in real time or near real time.
5) How does this opportunity support early warning and situational awareness?
A core purpose is to strengthen early warning and situational awareness so officials can identify emerging drug threats sooner, anticipate outbreaks, and respond more quickly with interventions that better protect the public.
6) Who is the intended participant group in the research experiences?
The program is designed around graduate students and recent post-graduates who will carry out the applied research studies and advanced analyses as part of a structured research experience.
7) What type of federal funding mechanism is used?
Funding is provided through a cooperative agreement. This typically indicates substantial federal involvement during the period of performance, such as collaboration on priorities, coordination activities, or technical guidance, rather than a fully hands-off grant model.
8) How many awards does ONDCP expect to make?
ONDCP expects to make one award under this opportunity.
9) What is the maximum award amount (award ceiling)?
The award ceiling is $100,000.
10) When was this opportunity created, and what is the application deadline?
The opportunity was created on August 6, 2026. The original application closing date is September 6, 2026, which creates a short preparation timeline for applicants.
11) Who is eligible to apply?
Eligible applicants include:
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Nonprofit organizations with 501(c)(3) status (excluding institutions of higher education under that specific nonprofit category)
12) What is the sponsoring agency?
The sponsoring agency is the Office of National Drug Control Policy (ONDCP).
13) What is the funding opportunity number?
The funding opportunity number is RD-AL-RDAAL-26-001. Applicants can use this identifier to locate the full announcement and submission instructions in the official system.
14) What CFDA number is associated with this opportunity?
The opportunity is associated with CFDA number 95.007.
15) What funding activity category is this opportunity listed under?
The program is listed under a health-related funding activity category.
16) What kinds of outcomes is ONDCP aiming for?
This opportunity is designed to achieve two outcomes at once: (1) develop the next generation of applied drug policy researchers, and (2) produce high-quality analyses that help government and community partners respond more effectively to a quickly evolving illicit drug environment.
17) How is this opportunity connected to the National Drug Control Strategy?
The applied research studies and advanced analyses are expected to directly support the National Drug Control Strategy by producing findings that can be used by decision-makers across public health and public safety.
18) What general approach is expected from the funded project?
The funded project is expected to operate as an applied research pipeline: a structured program that trains early-career researchers while generating timely, policy-relevant research products that can inform strategy and response.
Browse more opportunities from the same category: Health
Next opportunity: SOI - Rural Transportation Match and Gap Funding Assistance Program
Previous opportunity: BJA FY25 Forensic Ballistics and Higher Education Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RD AL RDAAL 26 001
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RD AL RDAAL 26 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| Nonfatal Overdoses in Emergency Departments: Bridging Patient Characteristics, Biospecimen Toxicology, and Drug Supply Composition Apply for EDS EDS 26 001 Funding Number: EDS EDS 26 001 Agency: Office of National Drug Control Policy Category: Health Funding Amount: $500,000 |
| Improving The Capacity of Tribal Communities to Identify Emerging Drug Threats Apply for RD ET RDA 26 001 Funding Number: RD ET RDA 26 001 Agency: Office of National Drug Control Policy Category: Health Funding Amount: $300,000 |
| Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed) Apply for RFA AG 27 010 Funding Number: RFA AG 27 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) (R03 Clinical Trial Optional) Apply for PAR 27 096 Funding Number: PAR 27 096 Agency: National Institutes of Health Category: Health Funding Amount: $125,000 |
| BRAIN Initiative: Integrative Team-Research BRAIN Circuits Program - iBCP (RM1 Clinical Trial Not Allowed) Apply for RFA NS 27 002 Funding Number: RFA NS 27 002 Agency: National Institutes of Health Category: Health Funding Amount: $8,000,000 |
| Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional) Apply for PAR 28 062 Funding Number: PAR 28 062 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required) Apply for PAR 27 065 Funding Number: PAR 27 065 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required) Apply for RFA DK 27 139 Funding Number: RFA DK 27 139 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed) Apply for PAR 27 051 Funding Number: PAR 27 051 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional) Apply for PAR 27 127 Funding Number: PAR 27 127 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required) Apply for RFA CA 27 005 Funding Number: RFA CA 27 005 Agency: National Institutes of Health Category: Health Funding Amount: $700,000 |
| Limited Competition: Centers of Biomedical Research Excellence: Development Phase (COBRE-D) (P30 - Clinical Trial Not Allowed) Apply for PAR 27 054 Funding Number: PAR 27 054 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required) Apply for RFA DK 27 125 Funding Number: RFA DK 27 125 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cooperative Centers for Experimental Hematology (CCEHs) (U54- Clinical Trial Not Allowed) Apply for RFA DK 27 127 Funding Number: RFA DK 27 127 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) Apply for RFA AI 27 002 Funding Number: RFA AI 27 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Institutional Development Award (IDeA) for Clinical & Translational Research (CTR) (P30 - CT Optional) Apply for PAR 27 056 Funding Number: PAR 27 056 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Not Allowed) Apply for PAR 27 112 Funding Number: PAR 27 112 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: NIGMS Mature Synchrotron Resources (MSR) for Structural Biology (P30 - Clinical Trial Not Allowed) Apply for PAR 27 068 Funding Number: PAR 27 068 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Long-term health outcomes of people living with spina bifida Apply for CDC RFA DD 26 0222 Funding Number: CDC RFA DD 26 0222 Agency: Centers for Disease Control - NCBDDD Category: Health Funding Amount: $300,000 |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) Apply for RFA AI 27 005 Funding Number: RFA AI 27 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RD AL RDAAL 26 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.